#	Aladdin ID	Assay Type	Description	Organism	Compounds	Reference	BAO Format	Source
1.	ALA1926118	B	Inhibition of CDK2/cyclin E		36	ALA1921760	protein complex format	Scientific Literature
2.	ALA1926135	B	Inhibition of CDK9/cyclin T1		4	ALA1921760	protein complex format	Scientific Literature
3.	ALA1926136	P	Solubility of the compound in water		5	ALA1921760	small-molecule physicochemical format	Scientific Literature
4.	ALA1926137	A	Cmax in BALB/c mouse plasma at 50 mg/kg, iv after 24 hrs by LC-MS analysis	Mus musculus	5	ALA1921760	organism-based format	Scientific Literature
5.	ALA1926138	A	AUC in BALB/c mouse plasma at 50 mg/kg, iv after 24 hrs by LC-MS analysis	Mus musculus	5	ALA1921760	organism-based format	Scientific Literature
6.	ALA1926139	A	Half life in BALB/c mouse plasma at 50 mg/kg, iv by LC-MS analysis	Mus musculus	5	ALA1921760	organism-based format	Scientific Literature
7.	ALA1926140	A	Volume of distribution in BALB/c mouse plasma at 50 mg/kg, iv after 24 hrs by LC-MS analysis	Mus musculus	5	ALA1921760	organism-based format	Scientific Literature
8.	ALA1926141	A	Clearance in BALB/c mouse plasma at 50 mg/kg, iv after 24 hrs by LC-MS analysis	Mus musculus	5	ALA1921760	organism-based format	Scientific Literature
9.	ALA1926142	A	Ratio of Seliciclib clearance to compound clearance in BALB/c mouse plasma at 50 mg/kg, iv after 24 hrs by LC-MS analysis	Mus musculus	4	ALA1921760	organism-based format	Scientific Literature
10.	ALA1926143	A	Oral bioavailability in BALB/c mouse at 50 mg/kg by LC-MS analysis	Mus musculus	4	ALA1921760	organism-based format	Scientific Literature
11.	ALA1926144	F	Antitumor activity against human HCT116 cells xenografted in NCR athymic mouse assessed as reduction in tumor volume at 50 mg/kg, po twice daily at 12 to 14 hrs intervals measured after 12 days relative to vehicle treated control	Homo sapiens	1	ALA1921760	organism-based format	Scientific Literature
12.	ALA1926145	F	Antitumor activity against human HCT116 cells xenografted in NCR athymic mouse assessed as growth delay at 50 mg/kg, po twice daily at 12 to 14 hrs intervals measured after 12 days relative to vehicle treated control	Homo sapiens	1	ALA1921760	organism-based format	Scientific Literature
13.	ALA1926146	B	Inhibition of CDK-mediated RB phosphorylation at Ser-780 in human HT29 cells at 0.1 to 20 uM after 24 hrs by Western blotting relative to control	Homo sapiens	1	ALA1921760	cell-based format	Scientific Literature
14.	ALA1926147	F	Reduction of RNA polymerase 2 expression in human HT-29 cells	Homo sapiens	1	ALA1921760	cell-based format	Scientific Literature
15.	ALA1926148	B	Inhibition of CDK7 in human HT29 cells assessed as reduction in RNA polymerase 2 expression	Homo sapiens	1	ALA1921760	cell-based format	Scientific Literature
16.	ALA1926149	B	Inhibition of CDK9 in human HT29 cells assessed as reduction in RNA polymerase 2 expression	Homo sapiens	1	ALA1921760	cell-based format	Scientific Literature
17.	ALA1926150	F	Cell cycle arrest in human HT-29 cells assessed as reduction at S phase at 3.3 uM up to 16 hrs measuring distribution of bromodeoxyuridine incorporation by flow cytometry	Homo sapiens	1	ALA1921760	cell-based format	Scientific Literature
18.	ALA1926218	F	Cell cycle arrest in human HT-29 cells assessed as accumulation at G2/M phase at 3.3 uM up to 16 hrs measuring distribution of bromodeoxyuridine incorporation by flow cytometry	Homo sapiens	1	ALA1921760	cell-based format	Scientific Literature
19.	ALA3705418	B	Kinase Assay: The compounds from the examples below were investigated for their CDK2/cyclin E, CDK1/cyclin B, CDK4/cyclin D1 and CDK7/cyclin H, ERK-2, and PKA inhibitory activity. His6-tagged recombinant human cyclin-dependent kinases CDK1/cyclin B1, CDK2/cyclin E, CDK4 and CDK7/cyclin H were expressed in sf9 cells using a baculovirus expression system. Recombinant cyclin D1 was expressed in E. coli. Proteins were purified by metal chelate affinity chromatography to greater than 90% homogeneity. Kinase assays were performed in 96-well plates using recombinant CDK/cyclins, recombinant active ERK-2 (Upstate Biotechnology), or cyclic AMP-dependent kinase (PKA) catalytic subunit (Calbiochem Cat. 539487). Assays were performed in assay buffer (25 mM beta -glycerophosphate, 20 mM MOPS, 5 mM EGTA, 1 mM DTT, 1 mM Na3VO3, pH 7.4), into which were added 2-4 ug of active enzyme with appropriate substrates (purified histone H1 for CDK2, recombinant GST-retinoblastoma protein (residues 773-928) for CDK4.	Homo sapiens	10	ALA3639056	cell-based format	BindingDB Database
20.	ALA3707754	B	Kinase Assay: The compounds from the examples below were investigated for their CDK2/cyclin E, CDK1/cyclin B, CDK4/cyclin D1 and CDK7/cyclin H, ERK-2, and PKA inhibitory activity. His6-tagged recombinant human cyclin-dependent kinases CDK1/cyclin B1, CDK2/cyclin E, CDK4 and CDK7/cyclin H were expressed in sf9 cells using a baculovirus expression system. Recombinant cyclin D1 was expressed in E. coli. Proteins were purified by metal chelate affinity chromatography to greater than 90% homogeneity. Kinase assays were performed in 96-well plates using recombinant CDK/cyclins, recombinant active ERK-2 (Upstate Biotechnology), or cyclic AMP-dependent kinase (PKA) catalytic subunit (Calbiochem Cat. 539487). Assays were performed in assay buffer (25 mM beta -glycerophosphate, 20 mM MOPS, 5 mM EGTA, 1 mM DTT, 1 mM Na3VO3, pH 7.4), into which were added 2-4 ug of active enzyme with appropriate substrates (purified histone H1 for CDK2, recombinant GST-retinoblastoma protein (residues 773-928) for CDK4.	Homo sapiens	10	ALA3639056	cell-based format	BindingDB Database